ChemoCentryx to Hold Second Quarter 2020 Financial Results Conference Call on Monday, August 10, 2020

Rhea-AI Summary

ChemoCentryx (Nasdaq: CCXI) is set to release its second quarter 2020 financial results on August 10, 2020, after market close. An executive management conference call will follow at 5:00 p.m. Eastern Time to discuss the results. Interested participants can join via phone or access a live and archived audio webcast through ChemoCentryx’s website. The company focuses on developing medications for inflammatory, autoimmune diseases, and cancer, with its lead drug candidate, avacopan (CCX168), having completed a pivotal Phase III trial in ANCA-associated vasculitis.

MOUNTAIN VIEW, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2020 financial results will be released after market close on Monday, August 10, 2020. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 10, 2020 to discuss these results and to answer questions.

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 6246545. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis.

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya                                                          
Executive Vice President,                                                           
Chief Financial and Administrative Officer           
investor@chemocentryx.com                                          

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
William Slattery, Jr., Burns McClellan
212.213.0006                
bslattery@burnsmc.com

FAQ

When will ChemoCentryx release its Q2 2020 financial results?

ChemoCentryx will release its Q2 2020 financial results after market close on August 10, 2020.

What time is the ChemoCentryx conference call for Q2 2020 results?

The conference call will start at 5:00 p.m. Eastern Time on August 10, 2020.

How can I access the ChemoCentryx Q2 2020 earnings call?

You can participate by dialing (877) 303-8028 for domestic calls or (760) 536-5167 for international calls. The conference ID number is 6246545. A live and archived audio webcast can also be accessed through ChemoCentryx's website.

What is ChemoCentryx's lead drug candidate?

ChemoCentryx's lead drug candidate is avacopan (CCX168), which has successfully completed a pivotal Phase III trial in ANCA-associated vasculitis.